In the Finnish Cancer Registry reports, the proportion of de novo metastatic PCa has recently been around 17%, higher than in Sweden [32], where the incidence of PCa is high and PSA screening is widely performed. This evidence concerns the gene KLK3 and posterior cortical atrophy.